Erschienen in:
28.04.2015 | Original Article
Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation
verfasst von:
Yanhong Wang, Jihua Tian, Haixiu Guo, Yang Mi, Ruijing Zhang, Rongshan Li
Erschienen in:
Clinical and Experimental Medicine
|
Ausgabe 2/2016
Einloggen, um Zugang zu erhalten
Abstract
IgA nephropathy (IgAN) is the most frequent form of glomerulonephritis worldwide. The role of oxidative stress and inflammation in the pathogenesis of IgAN has been reported. Intermedin (IMD) is a newly discovered peptide that is closely related to adrenomedullin. We have recently reported that IMD can significantly reduce renal ischemia/reperfusion injury by diminishing oxidative stress and suppressing inflammation. The present study was designed to explore whether IMD ameliorates IgAN via oxidative stress- and inflammation-dependent mechanisms. Our results showed that IMD administration resulted in the prevention of albuminuria and ameliorated renal pathomorphological changes. These findings were associated with (1) decreased renal TGF-β1 and collagen IV expression, (2) an increased SOD level and reduced MDA level, (3) the inhibition of the renal activation of NF-κB p65 and (4) the downregulation of the expression of inflammatory factors (TNF-α, MCP-1 and MMP-9) in the kidney. These results indicate that IMD in the kidney protects against IgAN by reducing oxidative stress and suppressing inflammation.